-
Brown & Brown Gains 40% YTD: Will the Rally Last?
2024 Aug 13, 2:20pm | 707Brown & Brown, Inc.'s (NYSE: BRO) shares have jumped 40% year to date (YTD) compared with the industry's growth of 20.6%. The Finance sector and the Zacks S&P 500 composite have risen 7.7% and 12.3%, respectively, in the same time frame. With a market capitalization of $28.61...
-
USA Compression Q2 Earnings & Revenues Top Estimates
2024 Aug 13, 2:11pm | 984USA Compression Partners (NYSE: USAC) reported a second-quarter adjusted net profit of 21 cents per common unit, which beat the Zacks Consensus Estimate of 17 cents due to its improved pricing and utilization. The metric also improved significantly from the year-ago quarter's adjusted net...
-
Should Quest Diagnostics be in Your Portfolio Now?
2024 Aug 13, 2:09pm | 997Quest Diagnostics Inc.'s (NYSE: DGX) sustained growth momentum within the legacy base business is poised to help it grow in the upcoming quarters. Strong progress in the company's highly specialized Advanced Diagnostics offerings is encouraging. Additionally, the cost discipline program,...
-
Itron Stock Up 33.1% in a Year: Will the Rally Continue?
2024 Aug 13, 2:06pm | 986Itron's (NASDAQ: ITRI) shares have been performing well on the trading front, with a gain of 33.1% year to date compared with 19.2% and 2.5% growth of the S&P 500 composite and the sub-industry, respectively. The stock is down 16.4% from its 52-week high level of $113.07, reflecting...
-
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
2024 Aug 13, 1:24pm | 1899The second-quarter earnings season has come to an end for large drug and biotech companies, with Eli Lilly (NYSE: LLY) reporting its results last week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical...
-
Sun Life Q2 Earnings Beat, Revenues Miss Estimates
2024 Aug 13, 1:22pm | 999Sun Life Financial Inc. (NYSE: SLF) delivered second-quarter 2024 underlying net income of $1.25 per share, which beat the Zacks Consensus Estimate by 5.9%. The bottom line increased 6.8% year over year. Underlying net income was $730.8 million (C$1 billion), which increased 9% year over year....
-
ArcelorMittal Closes Strategic 28% Stake Buy in Vallourec
2024 Aug 12, 4:11pm | 786ArcelorMittal S.A. (NYSE: MT) recently completed the acquisition of 65,243,206 shares, representing approximately 28.4% equity interest in Vallourec. This follows the signing of a Share Purchase Agreement on Mar 12, 2024, and the subsequent approval from relevant antitrust authorities and...
-
Bio-Rad Faces Low BioPharma Demand, Competitive Pressure
2024 Aug 12, 4:10pm | 961Bio-Rad's (NYSE: BIO) business performance has been affected by Biopharma's softness, macroeconomic conditions in China and competitive pressure. The stock carries a Zacks Rank #4 (Sell). Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where...
-
HUYA to Post Q2 Earnings: Expanding User Base to Aid Growth
2024 Aug 12, 3:39pm | 636Huya Inc. (NYSE: HUYA) is scheduled to report its second-quarter 2024 results on Aug 13. The Zacks Consensus Estimate for second-quarter revenues is pegged at $218.6 million, suggesting a decline of 12.96% year over year. The consensus mark for second-quarter earnings has remained unchanged at 7...
-
Royal Gold Earnings Beat Estimates in Q2, Rise Y/Y
2024 Aug 12, 3:38pm | 567Royal Gold, Inc. (NASDAQ: RGLD) reported adjusted earnings per share of $1.25 in second-quarter 2024, beating the Zacks Consensus Estimate of $1.17. The bottom line increased 42% year over year. Including one-time items, the company reported an EPS of $1.23 compared with the prior-year quarter'...
-
Lowe's Q2 Earnings on the Deck: Key Factors to Note
2024 Aug 12, 2:19pm | 1036As Lowe's Companies, Inc. (NYSE: LOW) prepares to unveil its second-quarter fiscal 2024 earnings on Aug 20 before the opening bell, investors are keenly observing the company's performance. With a projected decline in both the top and bottom-line figures, the upcoming earnings release...
-
Estee Lauder Earnings Expected to Grow: Should You Buy?
2024 Aug 12, 1:46pm | 869The market expects Estee Lauder (NYSE: EL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might...
-
Ironwood Q2 Earnings & Revenues Fall Shy of Estimates
2024 Aug 09, 4:03pm | 942Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter. Total revenues in the...
-
Broadwind Gears Up to Report Q2 Earnings: What to Expect
2024 Aug 09, 3:50pm | 733Broadwind, Inc. (NASDAQ: BWEN) is expected to release second-quarter 2024 results on Aug 13, after market close. The company's earnings beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 95.5%. In the last reported quarter, its earnings of 7 cents...
-
Embecta Corp. Tops Q3 Earnings and Revenue Estimates
2024 Aug 09, 2:15pm | 638Embecta Corp. (NASDAQ: EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings...
Coverage of Earnings Beats.